Adlai Nortye Biopharma Co., Ltd.
Registry sponsor category
Industry
- Other names
- Adlai Nortye Biopharma Co., Ltd.
- Company name
- Adlai Nortye Biopharma Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (11)
- A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression
- A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
- An Initial Evaluation of AN8025 in Solid Tumors
- AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
- AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
- Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
- Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
- First in Human, Dose Escalation Study of AN4005
- Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
- Preoperative Radiotherapy and E7046 in Rectum Cancer
- The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC